Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 7Genitourinary 4Other hematologic neoplasm 2Endocrine 2CNS 2Thoracic 1NET 1Lymphoid 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Neuroendocrine Tumors 111Gastro-enteropancreatic neuroendocrine tumor 19Carcinoma, Neuroendocrine 12Stomach Neoplasms 11Pancreatic Neoplasms 10Neoplasms 10Breast Neoplasms 10Pheochromocytoma 9Carcinoid Tumor 9Prostatic Neoplasms 8Paraganglioma 8Neoplasm Metastasis 8Carcinoma, Hepatocellular 8Adenoma, Islet Cell 8Thyroid Neoplasms 7Sarcoma 7Gastrointestinal Neoplasms 7Esophageal Neoplasms 7Colorectal Neoplasms 7Lung Neoplasms 6Rectal Neoplasms 5Ovarian Neoplasms 5Neuroblastoma 5Melanoma 5Liver Neoplasms 5Colonic Neoplasms 5Anus Neoplasms 5Uterine Cervical Neoplasms 4Gastrointestinal Stromal Tumors 4Cholangiocarcinoma 4

Interventions

lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Hypertension × NET × Clear all
NCT03206060 2026-04-24

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
130 enrolled
CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡